Hokkaido University · 의학
켄지 히라타 교수의 연구실은 정량적 PET 영상 기반 종양 생물학의 이해를 핵심으로 하며, 특히 암 치료 반응 예측과 생존 예후 평가를 위한 정량적 분석 기법을 개발하고 있습니다. 주로 F-18 FDG와 <sup>18</sup>F-FMISO를 활용한 PET 영상 분석을 통해 종양의 대사 활성 및 저산소 상태를 비침습적으로 평가하며, 이는 치료 계획 수립과 예후 예측에 기여합니다. 특히 간의 SUV 기반 정량화 방법 개선을 통해 임상적 일관성과 객관성을 높이는 데에도 기여하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Our semi-automated method could define the liver SUV robustly as the threshold value used for tumor volume measurements according to PERCIST. The method could avoid possible subjective bias of manual liver VOI placement and is thus expected to improve clinical performance of volume-based parameters for prediction of cancer treatment response.
Glioma is the most common malignant brain tumor. Hypoxia is closely related to the malignancy of gliomas, and positron emission tomography (PET) can noninvasively visualize the degree and the expansion of hypoxia. Currently, <sup>18</sup>F-fluoromisonidazole (FMISO) is the most common radiotracer for hypoxia imaging. The clinical usefulness of FMISO PET has been established; it can distinguish glioblastomas from lower-grade gliomas and can predict the microenvironment of a tumor, including necro
Positron emission tomography (PET) has unique characteristics for quantitative assessment of tumour biology in vivo. Accumulation of F-18 fluorodeoxyglucose (FDG) may reflect tumour characteristics based on its metabolic activity. Quantitative assessment of FDG uptake can often be applied for treatment monitoring after chemotherapy or chemoradiotherapy. Numerous studies indicated biochemical change assessed by FDG PET as a more sensitive marker than morphological change estimated by CT or MRI. I
